Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 19/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6478915 | 0.88 | OPRK1 (0.71) | OPRK1OPRD1OPRM1CYP2D6CYP3A4 | |
| SCHEMBL6486923 | 0.88 | OPRK1 (0.65) | OPRK1OPRD1OPRM1CYP2D6CYP3A4 | |
| SCHEMBL6479859 | 0.87 | OPRK1 (0.63) | OPRK1OPRD1OPRM1CYP2D6CYP3A4 | |
| Hydrochloric Acid SCHEMBL6478268 | 0.85 | OPRK1 (0.75) | OPRK1OPRD1OPRM1CYP2D6CYP3A4 | |
| Hydrochloric Acid SCHEMBL6478271 | 0.85 | OPRK1 (0.75) | OPRK1OPRD1OPRM1CYP2D6CYP3A4 | |
| SCHEMBL5629391 | 0.84 | OPRK1 (0.72) | OPRK1OPRD1OPRM1CYP2D6CYP3A4 | |
| SCHEMBL6478177 | 0.83 | OPRK1 (0.71) | OPRK1OPRD1OPRM1CYP2D6CYP3A4 | |
| SCHEMBL5843563 | 0.80 | OPRK1 (1.00) | OPRK1OPRD1OPRM1CYP2D6CYP3A4 | |
| SCHEMBL5843567 | 0.80 | OPRK1 (1.00) | OPRK1OPRD1OPRM1CYP2D6CYP3A4 | |
| Hydrochloric Acid SCHEMBL5844901 | 0.79 | OPRK1 (0.98) | OPRK1OPRD1OPRM1CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750216-B2 | HETEROCYCLIC AMINES SUCH AS 2-(2-(N-METHYLSULFAMOYL)-4-METHOXY -PHENYL)-N-METHYL-N-((1S)-1-PHENYL-2-((1-PYRROLIDINYL)ETHYL)) ACETAMIDE, ADMINISTERED AS ANALGESICS | ADOLOR CORPORATION | 2004-06-15 | — | — | US | claimed |
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2003-07-31 | — | — | US | claimed |
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2005-01-27 | — | — | US | disclosed |
| US-6750216-B2 | HETEROCYCLIC AMINES SUCH AS 2-(2-(N-METHYLSULFAMOYL)-4-METHOXY -PHENYL)-N-METHYL-N-((1S)-1-PHENYL-2-((1-PYRROLIDINYL)ETHYL)) ACETAMIDE, ADMINISTERED AS ANALGESICS | ADOLOR CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885OPRD1 2/4885OPRM1 3/4885 |
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885OPRD1 2/4885OPRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.